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Objectives. According to the updated FIGO system, positive peritoneal cytology does not affect endometrial
cancer stage. This revision may reduce rates of obtaining cytology, with unclear implications in advanced dis-
ease. This study evaluates the signiﬁcance of positive cytology in stage III (FIGO 2009) endometrial cancer.
Methods. Eligible patients received treatment for stage III endometrial cancer at a single institution and
had peritoneal cytology performed.
Results. Of 196 patients, 58% were≥60 years old, 48% had deep myometrial invasion, 71% lymphovascular
invasion, 25% cervical invasion, 37% adnexal involvement, 79% nodal involvement, and 46% aggressive histol-
ogy. Positive cytologywas present in 23% (45/196) and signiﬁcantly associated with cervical stromal invasion,
adnexal involvement, and aggressive histology (P ≤ 0.03). There was no signiﬁcant difference in rates of
lymphadenectomy, chemotherapy, or radiation between negative and positive cytology groups. At a median
follow-up of 47 months, the 5-year freedom from relapse was 39% for positive cytology vs. 69% for negative,
disease-speciﬁc survival 42% vs. 77%, and overall survival 34% vs. 72% (P b 0.001). Positive cytology correlated
with higher recurrence rates in the para-aortic nodes and peritoneum (30% vs. 9%, 23% vs. 4%; P ≤ 0.008).
When controlling for adverse features including aggressive histology, positive cytology was associated with
an increased hazard for relapse (HR 2.3; P = 0.002) and death (HR 2.9; P b 0.001).
Conclusions. In stage III endometrial cancer, positive cytology independently predicts outcome and is
associated with distinct relapse patterns. Obtaining peritoneal cytology in stage III endometrial cancer is
critical.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Until recently, the presence of positive peritoneal cytology alone
was sufﬁcient for endometrial cancer patients to be staged as IIIACancer Center, Department of
5, USA. Fax: +1 212 639 2417.
nc. Open access under CC BY-NC-ND license[1]. However, multiple researchers reported that positive cytology
as the sole extent of extra-uterine disease was associated with a prog-
nosis better than adnexal or serosal involvement and equivalent to
stage I disease [2–4]. These ﬁndings suggested that in otherwise early
stage endometrial cancer, positive cytology does not independently
predict outcome, and different clinical and pathological features deter-
mine prognosis. Other data, however, have demonstrated that positive
cytology is an independent risk factor in both early and advanced
stage disease [5–10].
Given this uncertainty, the most recent version of the International
Federation of Gynecology and Obstetrics (FIGO) staging system, adopted.
50 S.A. Milgrom et al. / Gynecologic Oncology 130 (2013) 49–53in 2009, states that “positive cytology has to be reported separatelywith-
out affecting the stage” [11]. Because cytology results no longer alter the
stage, this revisionmay lead to a decline in obtaining peritoneal cytology
in endometrial cancer. While this change in practice may have little
impact in early stage disease, the implications for stage III patients are
unclear. The purpose of this study was two-fold: ﬁrst, to determine the
prognostic signiﬁcance of positive peritoneal cytology, independent of
other risk factors, in stage III (FIGO 2009) endometrial cancer patients
treated at a single institution, and second, to evaluate its impact on pat-
terns of relapse.Materials and methods
Study design
After obtaining Institutional Review Board approval, stage III
(FIGO 2009) endometrial cancer patients who underwent total
hysterectomy and bilateral salpingo-oophorectomy at a single in-
stitution from 1995 to 2009 were identiﬁed retrospectively. Inclu-
sion criteria comprised the diagnosis of uterine adenocarcinoma
and examination of peritoneal cytology at the time of deﬁnitive
surgery. Patients with uterine carcinosarcoma or with prior pelvic
irradiation or chemotherapy receipt were excluded. Also excluded
were patients with isolated nodal tumor cells, detected by immu-
nohistochemistry only. Ultimately, 196 patients met the eligibility
criteria.
Adjuvant therapy, consisting of radiation therapy (RT) and/or che-
motherapy (CT), was provided at the discretion of the treatingmedical
and radiation oncologists. RT consisted of external beam RT (EBRT)
and/or intravaginal brachytherapy (IVRT). The intended course of
pelvic EBRT was to a total dose of 45 to 50.4 Gy, at 1.8 Gy per fraction.
Patients with para-aortic nodal involvement received extended ﬁeld
EBRT to a total dose of 45 Gy. IVRT was administered using a vaginal
cylinder and a high dose rate 192Ir remote afterloader. The IVRT dose,
prescribed to a depth of 0.5 cm from the applicator surface,was typically
21 Gy in 3 fractions when administered alone and 15 Gy in 3 fractions
when administered with EBRT.
Adjuvant CT was administered alone or in combination with RT.
The intended treatment for patients receiving CT alone was 6 cycles
of carboplatin (area under the curve = 5 or 6) and paclitaxel
(175 mg/m2). Therewere 3 patientswhowere treatedwith doxorubi-
cin (45 mg/m2), cisplatin (50 mg/m2), and paclitaxel (160 mg/m2) on
a protocol. The intended CT for patientswho also received EBRTwas con-
current cisplatin (40 or 50 mg/m2), followed by 4 cycles of carboplatin
(area under the curve = 5 or 6) and paclitaxel (175 mg/m2).
Patient follow-up included a history and physical examination
every 3 months for the ﬁrst 2 years after treatment, then every
6 months for the subsequent 3 years. A Papanicolaou smear and im-
aging of the chest, abdomen, and pelvis were performed twice a year
for 2 years, then annually for the subsequent 3 years. All recurrences
were biopsy-proven.Statistical analysis
The χ2 test was used to compare characteristics of patients with
positive vs. negative cytology. Kaplan–Meier methods were used to
calculate freedom from relapse, disease-speciﬁc survival, and overall
survival, and differences were tested using the log-rank test. The time
to relapse or death was measured from the date of surgery. Patients
with no event were censored at the time of last follow-up. Variables
that were not signiﬁcantly associated with outcome on Cox regression
analysiswere removed fromamultivariatemodel in a step-wise fashion.
Statistical analysis was performed using IBM SPSS software. P values
≤ 0.05 were considered signiﬁcant.Results
Patient characteristics
The median age at diagnosis was 62 years (range 33–86 years). Of
the 196 patients, 114 (58%) were ≥60 years old and 156 (80%) were
post-menopausal. In all cases, deﬁnitive surgery consisted of total
hysterectomy, bilateral salpingo-oophorectomy, and peritoneal cytol-
ogy. Pelvic lymphadenectomy was performed in 181 cases (92%),
with a median of 14 lymph nodes (LN) removed (range 1–51 LN).
Para-aortic lymphadenectomy was performed in 142 cases (72%;
median 6 LN; range 1–34 LN). Ninety-four patients (48%) had ≥50%
myometrial invasion, 139 (71%) lymphovascular invasion, 49 (25%)
cervical stromal invasion, 73 (37%) adnexal/serosal involvement,
and 154 (79%) nodal involvement. The histology was grade 1 or 2
endometrioid in 106 patients (54%). Aggressive histology, deﬁned as
grade 3 endometrioid (n = 25, 13%), papillary serous (n = 51, 26%),
clear cell (n = 12, 6%), or undifferentiated (n = 2, 1%), was seen in
the remaining 90 patients (46%). Peritoneal cytology was positive
in 45 patients (23%) and negative in 151 (77%). Only 4 patients had
gross residual disease post-operatively, and all 4 had negative cytology.
Adjuvant therapy
Adjuvant therapy, consisting of CT and/or RT, was administered to
183 patients (93%). The remaining 13 patients (7%) declined adjuvant
treatment. Forty-ﬁve patients (23%) received CT alone, of whom
40 (89%) received 6 cycles of carboplatin and paclitaxel, and 2 (4%)
received 6 cycles of carboplatin, with paclitaxel discontinued after
1–2 cycles due to toxicity. Three patients (7%) received 7 cycles of
doxorubin, cisplatin, and paclitaxel on a protocol. Forty-ﬁve patients
(23%) received RT alone. Of these, 30 (67%) received EBRT (median
50.4 Gy; range 41.4–50.4 Gy); 14 (31%) received a combination of
EBRT (median 47.7 Gy; range 39.6–50.4 Gy) and IVRT (median 15 Gy;
range 12–21 Gy); and 1 (2%) received IVRT alone (21 Gy).
Ninety-three patients (47%) received chemoradiation. Of these, 67
(72%) received EBRT (median 50.4 Gy; range 18–50.4 Gy); 11 (12%)
received IVRT (median 21 Gy; range 18–30 Gy); and the remaining
15 (16%) received IVRT (median 15 Gy; range 5–20 Gy) plus EBRT
(median 45 Gy; range 45–50.4 Gy). The majority of patients (n =
53, 65%) treated with EBRT received cisplatin concurrently and carbo-
platin and paclitaxel after the completion of EBRT. Those treated with
IVRT alone received carboplatin and paclitaxel only.
Positive vs. negative peritoneal cytology groups
The positive cytology (n = 45) and negative cytology (n = 151)
groups were comparable with respect to age ≥60 years, deep
myometrial invasion, and lymphovascular invasion (Table 1). There
was no difference in the rate of pelvic (84% vs. 90%, P = 0.294) or
para-aortic (67% vs. 77%, P = 0.323) lymphadenectomy or of nodal
involvement; pelvic nodes were involved in 62% of patients with
positive cytology vs. 67% with negative (P = 0.563), and para-aortic
nodes were involved in 33% vs. 34% (P = 0.956). Additionally, there
was no statistically signiﬁcant difference in the use of adjuvant RT
or CT. There were, however, signiﬁcantly more patients in the positive
cytology group with aggressive histology (60% vs. 42%; P = 0.031),
cervical stromal invasion (38% vs. 21%; P = 0.024), and adnexal/
serosal involvement (53% vs. 32%; P = 0.011), when compared to
the negative cytology group.
Patterns of relapse
Of the 196 patients, 61 (31%) relapsed at one ormore sites. The sites
of recurrence were the pelvis in 19 patients (7%), the para-aortic nodes
in 21 (8%), the peritoneum in 14 (5%), and distant in 32 (12%). In the
Fig. 1. Outcomes of patients with positive versus negative peritoneal cytology. A. Free-
dom from relapse; B. disease-speciﬁc survival; C. overall survival. Solid line = negative
peritoneal cytology; dotted line = positive peritoneal cytology.
Table 1
Characteristics of patients with positive versus negative peritoneal cytology.
Positive
cytology
(n = 45)
Negative
cytology
(n = 151)
P-value
n (%) n (%)
Age ≥60 years 23 (51) 91 (60) 0.275
b60 years 22 (49) 60 (40)
Myometrial invasion ≥50% 25 (56) 69 (46) 0.245
b50% 20 (44) 82 (54)
Lymphovascular invasion Present 32 (71) 107 (71) 0.974
Absent 13 (29) 44 (29)
Cervical stromal invasion Present 17 (38) 32 (21) 0.024
Absent 28 (62) 119 (79)
Aggressive histology Yes 27 (60) 63 (42) 0.031
No 18 (40) 88 (58)
Adnexal/serosal involvement Yes 24 (53) 49 (32) 0.011
No 21 (47) 102 (68)
Pelvic lymph node dissection Yes 38 (84) 136 (90) 0.294
No 7 (16) 15 (10)
Pelvic lymph node involvement Yes 28 (62) 101 (67) 0.563
No 17 (38) 50 (33)
Para-aortic lymph node
dissection
Yes 30 (67) 112 (77) 0.323
No 15 (33) 39 (23)
Para-aortic lymph node
involvement
Yes 15 (33) 51 (34) 0.956
No 30 (67) 100 (66)
Radiation therapy Received 27 (60) 111 (74) 0.081
Did not receive 18 (40) 40 (26)
Chemotherapy Received 36 (80) 102 (68) 0.108
Did not receive 9 (20) 49 (32)
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pared to 39/151 (26%) in the negative cytology group (P = 0.003).
The patterns of relapse differed for the positive and negative cytol-
ogy groups (Table 2). Patients with positive cytology experienced a
signiﬁcantly greater number of recurrences in the para-aortic nodes
(20% vs. 8%, P = 0.022) and peritoneum (20% vs. 3%, P b 0.001). The
incidence of recurrence in the pelvis (11% vs. 9%, P = 0.714) and
other distant sites (18% vs. 16%, P = 0.764) was similar between
the two groups.
Outcome
With a median follow-up of 47 months (range 3–165), the 5-year
freedom from relapse (FFR) was 63% (95% CI: 55–71) for the whole
cohort. This rate was 39% (95% CI: 21–57) for the positive cytology
group, compared to 69% (95% CI: 61–77) for negative cytology
(P b 0.001; Fig. 1A). Other signiﬁcant predictors of poor FFR on
univariate analysis were deep myometrial invasion (55% vs. 71%,
P = 0.014), aggressive histology (44% vs. 81%, P b 0.001), omission
of pelvic lymphadenectomy (38% vs. 67%, P = 0.005), and omission
of adjuvant RT (45% vs. 71%, P b 0.001) (Table 3). On multivariate
analysis, positive peritoneal cytology retained its signiﬁcant associa-
tion with risk of relapse (HR 2.3, 95% CI: 1.3–3.9; P = 0.002). Other
independent predictors of poor FFR were deep myometrial invasion
(HR 2.2, 95% CI 1.3–3.7; P = 0.003), aggressive histology (HR 4.0,Table 2
Patterns of relapse for patients with positive versus negative peritoneal cytology.
Positive cytology
(n = 45)
Negative cytology
(n = 151)
P-value
Pelvic recurrence
rate at 5 years
14% 11% 0.581
(n = 5) (n = 14)
Para-aortic recurrence
rate at 5 years
30% 9% 0.008
(n = 9) (n = 12)
Peritoneal recurrence
rate at 5 years
23% 4% b0.001
(n = 9) (n = 5)
Distant recurrence
rate at 5 years
27% 20% 0.385
(n = 8) (n = 24)95% CI: 2.3–7.3; P b 0.001), and omission of adjuvant RT (HR 1.9,
95% CI: 1.1–3.2; P = 0.013).
There were a total of 70 deaths, of which 51 were from endometrial
cancer. The 5-year disease-speciﬁc survival (DSS) was 69% (95% CI:
61–77) for the entire cohort. This rate was 42% (95% CI: 25–59) for pos-
itive cytology vs. 77% (95% CI: 69–85) for negative (P b 0.001; Fig. 1B).
Other factors associated with worse DSS on univariate analysis were
deepmyometrial invasion (64% vs. 73%, P = 0.053), aggressive histolo-
gy (54% vs. 82%, P b 0.001), omission of pelvic lymphadenectomy
(43% vs. 72%, P = 0.005), and omission of adjuvant RT (60% vs. 72%,
P = 0.010) (Table 3). On multivariate analysis, positive cytology
retained a signiﬁcant association poor DSS (HR 2.9, 95% CI: 1.6–5.1;
Table 3
Univariate analyses. CI = conﬁdence interval; DSS = disease-speciﬁc survival; FFR =
freedom from recurrence; OS = overall survival.
Univariate analyses
5-year FFR
rate (95% CI)
5-year DSS
rate (95% CI)
5-year OS
rate (95% CI)
Peritoneal cytology Positive 39% (21–57) 42% (25–59) 34% (17–51)
Negative 69% (61–77) 77% (69–85) 72% (63–81)
P b 0.001 P b 0.001 P b 0.001
Age ≥60 years 60% (50–70) 64% (53–75) 56% (45–67)
b60 years 68% (57–79) 76% (65–87) 74% (63–85)
P = 0.423 P = 0.336 P = 0.028
Myometrial invasion ≥50% 55% (44–66) 64% (53–75) 57% (45–69)
b50% 71% (61–81) 73% (62–84) 68% (56–80)
P = 0.014 P = 0.053 P = 0.039
Lymphovascular
invasion
Present 62% (52–72) 68% (58–78) 60% (50–70)
Absent 66% (52–80) 71% (57–85) 71% (57–85)
P = 0.465 P = 0.748 P = 0.090
Cervical stromal
invasion
Present 52% (36–68) 61% (45–77) 53% (37–69)
Absent 67% (58–76) 71% (62–80) 66% (56–76)
P = 0.064 P = 0.087 P = 0.041
Aggressive histology Yes 44% (32–56) 54% (42–66) 48% (36–60)
No 81% (73–89) 82% (72–92) 76% (66–86)
P b 0.001 P b 0.001 P b 0.001
Adnexal/serosal
involvement
Yes 69% (57–81) 71% (59–83) 65% (52–78)
No 60% (50–70) 67% (57–77) 61% (51–71)
P = 0.522 P = 0.823 P = 0.456
Pelvic lymph node
dissection
No 38% (16–60) 43% (21–65) 36% (16–56)
Yes 67% (59–75) 72% (64–80) 67% (58–76)
P = 0.005 P = 0.005 P = 0.007
Para-aortic lymph
node dissection
No 67% (53–81) 70% (54–86) 62% (46–78)
Yes 63% (54–72) 68% (59–77) 63% (54–72)
P = 0.921 P = 0.867 P = 0.925
Pelvic and/or para-aortic
nodal involvement
Yes 60% (51–69) 66% (57–75) 60% (51–69)
No 76% (62–90) 79% (64–94) 71% (55–87)
P = 0.098 P = 0.096 P = 0.049
Radiation therapy No 45% (29–61) 60% (45–75) 54% (40–68)
Yes 71% (62–80) 72% (63–81) 67% (57–77)
P b 0.001 P = 0.010 P = 0.006
Chemotherapy No 67% (53–81) 70% (56–84) 60% (46–74)
Yes 62% (52–72) 68% (58–78) 64% (54–74)
P = 0.597 P = 0.630 P = 0.618
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0.015) and aggressive histology (HR 3.7, 95% CI: 2.0–6.9; P b 0.001)
were also independent predictors of reduced DSS. The 5-year overall
survival (OS) rate was 63% (95% CI: 55–71) for the whole cohort, 34%
(95% CI: 17–51) for those with positive cytology, and 72% (95% CI:
63–81) for those with negative cytology (P b 0.001; Fig. 1C). On multi-
variate analysis, positive cytology (HR 2.9, 95% CI: 1.7–4.8; P b 0.001),
deep myometrial invasion (HR 1.9, 95% CI: 1.2–3.1; P = 0.011), and
aggressive histology (HR 3.1, 95% CI: 1.8–5.1; P b 0.001) were indepen-
dently associated with decreased OS.
Because patients with aggressive histologies were signiﬁcantly
more likely to have positive cytology, a separate multivariate analysis
was performed on the subset with grade 1 or 2 endometrioid adeno-
carcinoma (n = 106). In this group, positive cytology was associated
with a hazard ratio for relapse of 2.8 (95% CI: 1.0–8.3, P = 0.054),
cause-speciﬁc mortality of 3.5 (95% CI: 1.1–10.8, P = 0.034), and
overall mortality of 2.5 (95% CI: 1.0–6.5, P = 0.051).
Discussion
Unlike in early stage endometrial cancer, positive peritoneal cytol-
ogy is considered a poor prognostic factor in advanced stage disease
[6,7]. However, this ﬁnding is often attributed to the frequent associ-
ation with other adverse risk factors, such as stage IV disease and
aggressive histology. In the current study of 196 patients, limited to
FIGO 2009 stage III disease, the 5-year FFR, DSS, and OS were signiﬁ-
cantly worse for patientswith positive peritoneal cytology than for those
with negative cytology (P b 0.001). Positive cytology independentlypredicted risk of relapse (HR 2.3; P = 0.002) and death (HR 2.9;
P b 0.001), even when controlling for aggressive histology on multivari-
ate analysis. In the subset of patients with grade 1 or 2 endometrioid
adenocarcinoma, positive cytology was associated with a hazard ratio
for relapse of 2.8 (P = 0.054), endometrial cancer-speciﬁc mortality of
3.5 (P = 0.034), and overall mortality of 2.5 (P = 0.051).
Positive peritoneal cytology was associated not only with worse
outcomes, but also with unique recurrence patterns. Patients with
positive cytology were more likely to develop a peritoneal relapse
than those with negative cytology (23% vs. 4% at 5 years respectively,
P b 0.001).Mariani et al. also found that positive cytology independent-
ly predicted an increased risk of peritoneal relapse in stage I–III (FIGO
1988) endometrial cancer (RR = 6.72; P = 0.009) [12]. Additionally,
in the current study, the rate of relapse in the para-aortic nodes was
signiﬁcantly higher in patients with positive cytology (30% vs. 9% at
5 years, P =0.008). On the other hand, rates of relapse in the pelvis or
distant sites were similar in the two groups.
In the current study, 80% of patients with positive cytology re-
ceived adjuvant CT, compared to 68% of those with negative cytology
(P = 0.1). Thus, broader use of “standard” adjuvant CT may not im-
prove outcomes signiﬁcantly in the setting of positive cytology. Of
interest, the rate of adjuvant RT use was slightly lower for patients
with positive than negative cytology (60% vs. 74%), although this dif-
ference did not reach statistical signiﬁcance (P = 0.081). The omis-
sion of adjuvant RT was associated with a signiﬁcantly increased
hazard for recurrence (HR 1.9; P = 0.013), when controlling for
other prognostic variables on multivariate analysis. Other studies of
advanced stage endometrial cancer have also shown improved out-
comes associated with RT receipt. For example, in 122 endometrial
cancer patients with nodal metastases, Mariani et al. found a 5-year
pelvic relapse rate of 57% for patients who received an inadequate
nodal dissection and/or no adjuvant RT, compared to 10% for those
with an adequate dissection and adjuvant RT (P = 0.03) [13]. Klopp
et al. reported outcomes of a series of 71 node-positive endometrial
cancer patients who received adjuvant CT and/or RT after deﬁnitive
surgery. At a median follow-up of 67 months, patients who received
RT experienced improved 5-year pelvic relapse-free survival (98%
vs. 61%, P = 0.001), as well as disease-speciﬁc and overall survival
(78% vs. 39%, P = 0.01; 73% vs. 40%, P = 0.03) [14]. These ﬁndings
must be interpreted with caution, because RT may have been
recommended only for the most favorable patients. Nonetheless,
they call into question the prevailing wisdom of recommending adju-
vant CT alone for patients with positive cytology in the setting of FIGO
2009 stage III disease.
This retrospective study is not without limitations. However, every
attempt was made to collect as homogenous a cohort as possible by
excluding patients with early stage disease, in which the prognostic sig-
niﬁcance of positive peritoneal cytology isminimal, and excluding those
with stage IV disease, on the other end of the spectrum. Furthermore,
because patients treated before 1995 were excluded, the majority of
patients (92%) received a lymphadenectomy, so the data are applicable
to true surgical stage III disease.
In conclusion, positive peritoneal cytology is highly predictive of
poor outcome in stage III endometrial cancer, independent of other
adverse features, including aggressive histology. Additionally, positive
cytology is associated with distinct relapse patterns. Thus, although cy-
tology does not affect stage according to the current FIGO 2009 system,
it provides valuable information and must continue to be obtained.
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